Therefore, for kidney transplant recipients suffering from symptomatic COVID-19, clinicians should first choose to reduce or stop ADs or mTOR inhibitors instead of CNIs, and when the illness progresses to severely symptomatic COVID-19 at that time, the withdrawal of CNIs will be considered [23,56]. This evidence concerns the gene MTOR and COVID-19.